Bulletin: Transcatheter Cardiovascular Therapeutics (TCT)

There will be 16 late-breaker trials presented at the TCT meeting, sponsored by the Cardiovascular Research Foundation (CRF), in Denver from October 29 – November 2, 2017, along with 12 first report investigations.

Bulletin: Treatment Of Uterine Fibroids

The Society of Interventional Radiology (SIR) denies it is in a turf war with OB-GYNs over the treatment of uterine fibroids (leiomyoma), but there is tension. SIR is upset because they believe OB-GYNs are not informing women with uterine fibroids about a treatment option they can get from interventional radiologists. SIR president Suresh Vedantham, MD, from Washington University School of Medicine, said uterine fibroid embolization (UFE) – a procedure interventional radiologists provide – is “vastly underutilized.”

FDA Advisory Committee Recomends Approval Of Dynavax's Helplisav-b Vaccine

The FDA’s Vaccines and Related Biological Products Advisory Committee voted 12-1 (with 3 abstentions) that Dynavax Technologies’ Heplisav-B, a hepatitis B vaccine, is safe. The proposed indication is for immunization against infection caused by all known subtypes of hepatitis B virus in adults age ≥18. It would be administered in two 0.5 mL doses, given four weeks apart.

1 2 3 78